Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaJonathan D. Schoenfeld, Robert I. Haddad, Glenn J. Hanna et al.|JAMA Oncology|2020Cited by 350
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancerGiacomo Oliveira, Ravindra Uppaluri, Jonathan D. Schoenfeld et al.|Science Immunology|2023Cited by 118
Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck CancerLaura A. Goguen, Robert I. Haddad, Marshall R. Posner et al.|Otolaryngology|2006Cited by 105
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and NeckGlenn J. Hanna, Robert I. Haddad, Anne O’Neill et al.|Clinical Cancer Research|2021Cited by 104
Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck CancerLaura A. Goguen, Robert I. Haddad, Marshall R. Posner et al.|Archives of Otolaryngology - Head and Neck Surgery|2006Cited by 83